Search results
Showing 256 to 270 of 2009 results for nice guidelines
Headaches (update): Prophylactic treatment of migraine - Candesartan
In development Reference number: GID-NG10472 Expected publication date: TBC
Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.
Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)
This guideline covers the assessment, preparation, training and monitoring needed when using sedation in people aged under 19. It aims to help healthcare professionals decide when sedation is the most clinically and cost effective option for reducing pain and anxiety during operations for children and young people.
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline covers recognising and managing antisocial behaviour and conduct disorders in children and young people aged under 19. It aims to improve care by identifying children and young people who are at risk and when interventions can prevent conduct disorders from developing. The guideline also makes recommendations on communication, to help professionals build relationships with children and young people and involve them in their own care.
In development Reference number: GID-NG10445 Expected publication date: TBC
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
In development Reference number: GID-NG10451 Expected publication date: 17 December 2027
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
Suspected sepsis in under 16s: recognition, diagnosis and early management
In development Reference number: GID-NG10466 Expected publication date: 17 February 2027
This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
This quality standard covers the initial management of self-harm and the provision of longer-term support for children and young people (aged 8 to 18) and adults (aged 18 and over) who self-harm. It describes high-quality care in priority areas for improvement.
View quality statements for QS34Show all sections
Sections for QS34
- Quality statements
- Quality statement 1: Compassion, respect and dignity
- Quality statement 2: Initial assessments
- Quality statement 3: Psychosocial assessments
- Quality statement 4: Observation
- Quality statement 5: Safe physical environments
- Quality statement 6: Care plans
- Quality statement 7: Psychological interventions
Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing
In development Reference number: GID-NG10467 Expected publication date: 11 September 2026
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.